摘要
纳米抗体是骆驼来源的一种轻链缺失的抗体,具有与单克隆抗体相似的抗原结合特异性和亲和力,此外还具有分子量小、稳定性好、易于制备等优点,因而具有巨大的生物医药应用价值。本研究利用基因工程技术在大肠杆菌中成功制备出了高纯度的EGFR纳米抗体(antiEGFRnano)。CCK-8法检测细胞增殖及迁移实验(细胞划痕实验和Transwell法检测)证明,重组的EGFR纳米抗体具有显著的抑制子宫内膜癌细胞增殖及迁移的活性,这为靶向EGFR治疗子宫内膜癌提供了一种全新的思路和方法。
Nanobody is a kind of antibody from camel, which misses light chain. Nanobody has the same antigen binding specificity and affinity as mAb. Moreover, because of its small molecular weight, high stability and easy preparation, nanobody has great value of biomedical applications. In this study, we successfully prepared highly pure antiEGFR nanobody in E.coli using genetic engineering techniques. Cell proliferation assay （CCK-8 assay） and migration experiments （cell scratch test and Transwell assay） indicated that the recombinant antiEGFR can significantly inhibit the proliferation and migration of endometrial cancer cells. These results provide a new way of thinking and methods for EGFR-targeted therapy of endometrial cancer.
出处
《药学学报》
CAS
CSCD
北大核心
2012年第10期1341-1346,共6页
Acta Pharmaceutica Sinica
基金
江苏省自然科学基金资助项目(BK2009038)
江苏省企业博士集聚计划
